文献速递浆细胞疾病造血干细胞移植与细胞治疗

诱导治疗时长对新诊断多发性骨髓瘤患者接受 upfront 自体造血干细胞移植后生存的影响

Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation.
PubMed 文献 · Br J Haematol · 2018-04-29

该研究纳入2007至2014年在Mayo Clinic接受自体造血干细胞移植的596例新诊断多发性骨髓瘤患者,按诱导治疗时长分为≤4个月与>4个月两组。中位随访54.5个月,两组中位无进展生存期分别为28个月与26个月(P=0.605),总生存期无显著差异(P=0.904),在高危特征及不同移植前缓解深度亚组中结果一致。

要点

  • 诱导治疗≤4个月组中位PFS为28个月,>4个月组为26个月,P=0.605。
  • 两组总生存期无显著差异(P=0.904)。
  • 在高危特征及移植前缓解<VGPR或≥VGPR亚组中,诱导时长对PFS和OS均无影响。

核心结论

  • 在接受单线诱导治疗后以自体造血干细胞移植巩固的新诊断多发性骨髓瘤患者中,将诱导治疗延长至超过4个月不影响生存。

研究设计与样本

  • 回顾性纳入2007至2014年在Mayo Clinic接受自体造血干细胞移植的596例患者,按诱导治疗时长分为≤4个月组与>4个月组。

主要发现

  • 自移植起中位随访54.5个月,诱导≤4个月组中位PFS为28个月(95%CI 25-33),诱导>4个月组为26个月(95%CI 24-31),P=0.605。
  • 两组总生存期无显著差异(P=0.904)。
  • 在诊断时具有高危特征(国际分期系统III期或高危细胞遗传学)及移植前缓解深度≥VGPR或<VGPR的亚组中,诱导时长对PFS和OS均无影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal duration of induction therapy (IT) in transplant-eligible multiple myeloma (MM) patients in not well defined, resulting in a wide variation in clinical practice. The objective of our study was to determine whether the duration of IT in patients undergoing upfront autologous stem cell transplantation (ASCT) has an impact on progression-free survival (PFS) in the era of proteasome inhibitors and immunomodulatory drugs. A total of 596 patients who underwent ASCT at Mayo Clinic between 2007 and 2014 were included. The patients were divided into two cohorts based on the duration of IT: IT ≤ 4 and IT > 4 months. At a median follow-up of 54·5 months from ASCT, the median PFS in the IT ≤ 4 group was 28 months [95% confidence interval (CI), 25-33], compared to 26 months in the IT > 4 group (95% CI, 24-31) [P = 0·605]. There was no significant difference in overall survival (OS) in the two groups (P = 0·904). The lack of impact of IT duration on PFS and OS was consistent in subgroups with high-risk features at diagnosis (International Staging System III or high-risk cytogenetics) and different depths of pre-transplant response [≥very good partial response (VGPR) and <VGPR]. In conclusion, prolonging the duration of IT beyond 4 months does not impact survival in patients with newly diagnosed MM who complete a single line of IT followed by consolidation with ASCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chakraborty R, Muchtar E, Kumar SK, et al. Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. Br J Haematol. 2018. PMID: 29707759. doi:10.1111/bjh.15244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。